TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Prednisolone for Pain Reduction in Knee OA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Community-dwelling older adults aged 65 years and above with primary knee OA diagnosed according to the ACR criteria for diagnosis of primary OA of the knee~Exclusion Criteria:~* Any inflammatory or serious medical condition

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- prednisolone (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of Pulsed Electromagnetic Fields (PEMF) After Breast Reconstruction Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients who decide to have immediate unilateral TRAM flap breast reconstruction and are deemed candidates for this surgery. Patients who have undergone or will be undergoing sentinel lymph node or axillary lymph node dissection will be included.~Exclusion Criteria:~* Patients who are not candidates for TRAM flap reconstruction will be excluded. Specific reasons for a patient not to be a candidate will be determined by the surgeon, but may include patients who have minimal abdominal tissue, patients with multiple medical co-morbidities, patients who have had prior abdominal surgeries that preclude a pedicled operation, or patients who are morbidly obese.~* Additionally, patients who opt for a free TRAM flap or DIEP flap will be excluded since their abdominal donor site morbidity is different than a pedicled TRAM flap.~* Patients undergoing bilateral reconstruction will also be excluded, because of the more extensive nature of the surgery and donor-site morbidity, which might confound results.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Sham PEMF Device (Type: SHAM_COMPARATOR): Patients will receive inactive device
- PEMF Device (Type: ACTIVE_COMPARATOR): Patients will receive Ivivi Torino II PEMF Device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Shelter-Based Diet and Physical Activity Intervention for Homeless Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. at least 18 years of age,~2. willing and able to attend all study visits,~3. earn a score ≥ 4 on the REALM-SF indicating \> 6th grade literacy level,~4. physically able to walk and/or run for physical activity,~5. resident of the transitional shelter (must show Bridge ID badge), and~6. have been living in the transitional shelter for ≤ 3 months.~Exclusion Criteria:~1. \< 18 years of age,~2. unwilling or unable to attend all study visits,~3. earn a score \< 4 on the REALM-SF indicating ≤ 6th grade literacy level,~4. unable to participate in the walking/running component of the intervention (i.e., mobility impairments),~5. are not residents of the transitional shelter (or does not have a Bridge ID badge) or~6. have been living in the shelter for \> 2 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control Group (Type: NO_INTERVENTION): Control participants will be paid for assessments. They will receive study newsletters and a pedometer with advice after the final follow-up visit.
- Intervention Group (Type: ACTIVE_COMPARATOR): Intervention participants will receive 4 weekly newsletters, a pedometer with walking advice, and twice daily fruit/vegetable snacks during weekdays.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Buprenorphine in the Emergency Department

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Presenting to the ED in opioid withdrawal or soon to be in withdrawal~2. Minimum age 16~3. English speaking~4. Active phone number~5. Ontario Health Insurance Program card~Exclusion Criteria:~1. Pregnant~2. Currently enrolled in a methadone or buprenorphine maintenance~3. Benzodiazepine addiction (or taking \>50mg of valium equivalent/day)~4. Acute hepatitis or liver failure

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Buprenorphine (Type: EXPERIMENTAL): Patient receives buprenorphine in the emergency room based on a clinical trial protocol as well as a take home prescription for buprenorphine
- Clonidine (Type: ACTIVE_COMPARATOR): Patient receives clonidine in the emergency room based on a clinical trial protocol and also receives a take home prescription for clonidine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Confirmed diagnosis of PV according to the 2008 World Health Organization criteria, Non-palpable spleen, Phlebotomy dependent, Resistant to or intolerant of hydroxyurea, ECOG performance status of 0, 1 or 2.~Exclusion Criteria:~Inadequate liver or renal function, Significant bacterial, fungal, parasitic, or viral infection requiring treatment, Active malignancy within the past 5 years, excluding specific skin cancers, Previously received treatment with a JAK inhibitor, Being treated with any investigational agent, Women who are pregnant or nursing.~Other inclusion/exclusion criteria apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib (Type: EXPERIMENTAL): Ruxolitinib was administered at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid.
- Best Available Therapy (BAT) (Type: ACTIVE_COMPARATOR): Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation. Participants randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Present with a recent history of an ACS event based on the disease diagnostic criteria between 30 and 330 days prior to enrollment, and who state that they are supposed to be taking daily aspirin and maintenance dose 75-mg clopidogrel.~* Are of a legal age (and at least 18 years of age but less than 75 years of age) and competent mental condition to provide written informed consent before entering the study.~Exclusion Criteria:~* Left main coronary artery stent or left anterior descending (LAD) bifurcation stent.~* Have any form of coronary revascularization (percutaneous coronary intervention \[PCI\] or coronary artery bypass grafting \[CABG\]) planned to occur during the study (from signing consent through the final visit).~* Have undergone CABG or PCI within 30 days of entry into the study.~* Receiving or will receive oral anticoagulation or other antiplatelet therapy (other than aspirin and clopidogrel) that cannot be safely discontinued for the duration of the study.~* Receiving daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) that cannot be discontinued or are anticipated to require daily treatment with NSAIDs during the study.~* Have any of the following: history of ischemic or hemorrhagic stroke intracranial neoplasm, arteriovenous malformation, or aneurysm history of transient ischemic attack (TIA), have a body weight less than 60 kilograms (kg).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Prasugrel 10/10 mg (Type: EXPERIMENTAL): Open label (lead-in) dose of clopidogrel 75 milligram (mg) for 10 to 14 days. Upon completion, assignment to a single loading dose of prasugrel 10 mg and placebo, followed by maintenance dose of prasugrel 10 mg taken for 13 to 15 days.
- Clopidogrel 75/75 mg (Type: EXPERIMENTAL): Open label (lead-in) dose of clopidogrel 75 mg for 10 to 14 days. Upon completion, assignment to a single loading dose of clopidogrel 75 mg and placebo, followed by maintenance dose of clopidogrel 75 mg taken for 13 to 15 days.
- Prasugrel 60/10 mg (Type: EXPERIMENTAL): Open label (lead-in) dose of clopidogrel 75 mg for 10 to 14 days. Upon completion, assignment to a single loading dose of prasugrel 60 mg and placebo followed by maintenance dose of prasugrel 10 mg taken for 13 to 15 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Methylene Blue in Early Septic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Septic shock diagnosis, according to the Sepsis-3 consensus.~* Prior adequate fluid resuscitation according to dynamic predictors of volume responsiveness.~* More than 6 h and less than 24 h of norepinephrine requirement to maintain a mean arterial pressure ≥65 mmHg.~Exclusion Criteria:~* Age \< 18 years.~* Pregnancy.~* Not expected to survive 48 hours.~* Presence or high suspicion of concurrent hemorrhagic, obstructive or hypovolemic shock.~* Personal or familiar history of glucose-6-phosphate dehydrogenase deficiency.~* Allergic to methylene blue, phenothiazines, or food dyes.~* Recent intake (4-weeks) of selective serotonin re-uptake inhibitors.~* Refusal of the patient or decision maker to enroll in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Standard care (Type: PLACEBO_COMPARATOR): Placebo
- Methylene blue (Type: EXPERIMENTAL): Methylene blue

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ketamine for Acute Pain Management After Trauma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult trauma patients~* Admission to Shock Trauma ICU (STICU) or Surgical Intermediate Unit (SIMU)~* Randomization within 6 hours of arrival~Exclusion Criteria:~* Patient not expected to survive~* Contraindications to ketamine Allergy, Poorly controlled hypertension, Cardiac arrhythmia disorders (including atrial fibrillation), congestive heart failure, unstable coronary artery disease or recent myocardial infarction( MI)(within 6 months), cirrhosis, seizure disorder, and for those patients with unknown medical history - median sternotomy scar, mechanism of injury is fall from standing, 65 years of age or older, any arrhythmia on EKD)~* pregnancy~* in police custody~* history of dementia or movement disorder (i.e. Parkinson's)

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ketamine plus Usual care (Type: EXPERIMENTAL): None
- Usual care (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of allergic rhinitis~* In good health, determined by no clinically significant findings from medical history, 12-lead ECG, and vital signs~* Males or females who are surgically sterilized, post menopausal for the past year, or are using two acceptable methods of contraception against pregnancy through at least 6 months after the dose of study drug~Exclusion Criteria:~* History or clinical manifestations of significant metabolic, hepatic, renal, hematologic, immunodeficiency, pulmonary, cardiovascular, gastrointestinal, urologic, neurologic, or psychiatric disorders~* History of anaphylaxis, hypersensitivity or drug allergies~* Use of a non-biologic investigational drug or participation in an investigational study with a non-biologic drug within 30 days prior to dosing~* Use of a biologic investigational therapy or participation in an investigational study involving biologic therapy within 3 months prior to dosing~* Positive blood test for chronic viral infections by: hepatitis B surface antigen, hepatitis C virus antibody, or HIV antibody

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: EXPERIMENTAL): None
- C (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A In-Vivo Esophageal Protocol for Detection of Neoplasia in the Digestive Tract

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with Barrett's Esophagus or esophageal adenocarcinoma with or without confirmed Barrett's Esophagus~* Subjects who are scheduled for a clinically-indicated upper endoscopic evaluation and/or intervention (e.g. esophagogastroduodenoscopy (EGD) with biopsies)~* All subjects who are medically cleared for the procedure (e.g. washout for anticoagulants, co-morbidities) who meet the inclusion/exclusion will be included. Standard practice guidelines for safely proceeding with the procedure will be sufficient for our study~* Adults aged 18 years to 100~* Willing and able to sign informed consent~Exclusion Criteria:~* Subjects with known allergy or negative reaction to fluorescein or derivatives~* Subjects who have had an esophagectomy~* Subjects who are also prepped for colonoscopy with the EGD~* Subjects on active chemotherapy or radiation treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Application of peptide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stage 1 and Stage 2 FAP participants with the following:~  1. NIS score within protocol criteria~ 2. Documented transthyretin variant by genotyping~ 3. Documented amyloid deposit by biopsy~* Females of child-bearing potential must use appropriate contraception and be non-pregnant and non-lactating. Males engaging in relations of child-bearing potential are to use appropriate contraception~Exclusion Criteria:~* Low Retinol level at screen~* Karnofsky performance status ≤50~* Poor Renal function~* Known type 1 or type 2 diabetes mellitus~* Other causes of sensorimotor or autonomic neuropathy (for example, autoimmune disease)~* If previously treated with Vyndaqel®, will need to have discontinued treatment for 2 weeks prior to Study Day 1. If previously treated with Diflunisal, will need to have discontinued treatment for 3 days prior to Study Day 1~* Previous treatment with any oligonucleotide or siRNA within 12 months of screening~* Prior liver transplant or anticipated liver transplant within 1 year of screening~* New York Heart Association (NYHA) functional classification of ≥3~* Acute Coronary Syndrome or major surgery within 3 months of screening~* Known Primary or Leptomeningeal Amyloidosis~* Anticipated survival less than 2 years~* Any other conditions in the opinion of the investigator which interfere with the participant participating in or completing the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 82 Years
- Healthy Volunteers: f

Study Arms:
- Inotersen (Type: ACTIVE_COMPARATOR): 300 mg inotersen administered subcutaneously (SC) 3 times on alternate days in the first week and then once-weekly for 64 weeks
- Placebo (Type: ACTIVE_COMPARATOR): Placebo administered SC 3 times on alternate days in the first week and then once-weekly for 64 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacodynamic Study With Ticagrelor in African American Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of signed and dated informed consent before initiation of any study-related procedures~* Male or female patients aged 18 years or older~* Documented stable CAD fulfilling and taking 75-100mg ASA daily treatment~* Females must be post menopausal or surgically sterile Self-identified as African American~Exclusion Criteria:~* Any indication for oral anticoagulant (e.g., atrial fibrillation, mitral stenosis or prosthetic heart valve) or dual antiplatelet treatment (e.g., clopidogrel, prasugrel, ASA dose other than 75 to 100 mg daily) during study period~* Patients who had ACS or stent placed within 12 months of screening Patients with a history of moderate or severe hepatic impairment~* Current smokers, including the use of tobacco containing products in the past 1 month of randomization Patients required dialysis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ticagrelor (Type: EXPERIMENTAL): None
- Clopidogrel (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Botulinum Toxin Type A Injection Into the Gastrocnemius Muscle for Treatment of Nocturnal Calf Cramps in Patients With Lumbar Spinal Stenosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. diagnosed lumbar spinal stenosis with MRI finding~2. nocturnal calf cramps symptoms at least once per week~Exclusion Criteria:~1. electrolyte disorder~2. congenital muscle disease~3. muscle cramps related medication (statins, diuretics, calcium channel blockers, anticonvulsants etc.)~4. cognitive impairments

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- control group (Type: ACTIVE_COMPARATOR): None
- botox group (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ciprofloxacin for the Prevention of Meningococcal Meningitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Resident in a village included in the study area~Exclusion Criteria:~* Patients currently exhibiting symptoms of meningitis (to be immediately referred for further care)~* Persons with a known allergy to fluoroquinolone antibiotics.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Standard care (Type: NO_INTERVENTION): No chemoprevention for contacts of cases of meningitis (current standard of care) with a health promotion visit by a study nurse after the first notification of cases during the epidemic
- Household prophylaxis (Type: ACTIVE_COMPARATOR): Chemoprophylaxis with a single dose of oral ciprofloxacin for household members of reported cases of meningitis. For participants age \>12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age \<3 months: 75 mg (1.5 ml oral suspension).
- Village prophylaxis (Type: ACTIVE_COMPARATOR): Chemoprophylaxis with ciprofloxacin in the setting of a village-wide distribution after the notification of the first case of meningitis in a village. For participants age \>12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age \<3 months: 75 mg (1.5 ml oral suspension).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete